CRISPR-Cas13 emerges as a game changer in RNA-targeted therapies

In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the development of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) systems.

Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases

Beacon Therapeutics Holdings Limited has been launched to develop gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness.

June 12, 2023

Orphelia pushes boundaries with regulatory barriers for pediatric indications – Pharmaceutical Technology

Share this article Orphelia has developed Kizfizo as the first oral suspension of temozolomide to treat neuroblastoma. Credit: Nyaaka/Shutterstock.com Orphelia Pharma is taking action to

November 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

CRISPR-Cas13 emerges as a game changer in RNA-targeted therapies

Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases

Orphelia pushes boundaries with regulatory barriers for pediatric indications – Pharmaceutical Technology

Asymptomatic throat carriage is the key to transmission of Group A Streptococcus infections

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe